Castleview Partners’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$457K Buy
16,262
+2,767
+21% +$73.7K 0.23% 103
2025
Q4
$336K Buy
13,495
+2,322
+21% +$58.6K 0.17% 129
2025
Q3
$285K Buy
11,173
+1,896
+20% +$46.8K 0.15% 137
2025
Q2
$225K Buy
9,277
+38
+0.4% +$886 0.14% 158
2025
Q1
$234K Buy
9,239
+37
+0.4% +$968 0.16% 157
2024
Q4
$245K Buy
9,202
+1,086
+13% +$29.5K 0.13% 163
2024
Q3
$235K Buy
8,116
+99
+1% +$2.89K 0.14% 160
2024
Q2
$224K Buy
8,017
+1,352
+20% +$37.2K 0.13% 161
2024
Q1
$185K Buy
6,665
+1,786
+37% +$49.6K 0.1% 188
2023
Q4
$140K Buy
4,879
+1,638
+51% +$49.5K 0.1% 166
2023
Q3
$108K Sell
3,241
-5,267
-62% -$186K 0.1% 171
2023
Q2
$312K Sell
8,508
-3,699
-30% -$144K 0.28% 80
2023
Q1
$498K Buy
12,207
+287
+2% +$12.4K 0.44% 52
2022
Q4
$611K Sell
11,920
-548
-4% -$26.3K 0.59% 39
2022
Q3
$546K Buy
12,468
+10,576
+559% +$514K 0.52% 38
2022
Q2
$187K Sell
1,892
-14,415
-88% -$735K 0.15% 151
2022
Q1
$844K Sell
16,307
-902,933
-98% -$46.8M 0.53% 30
2021
Q4
$15.6K Buy
+919,240
New +$45.5M 0.12% 70
2021
Q2
$631K Buy
+16,111
New +$627K 0.28% 77
2018
Q1
$818K Buy
+24,307
New +$836K 0.68% 38

Other funds holding PFE

Castleview Partners's PFE Position: Q1 2026 in Review

Castleview Partners increased its Pfizer (PFE) stake by 21% in Q1 2026, buying an estimated $73.7K and bringing the position to 16,262 shares worth $457K. The position accounts for 0.23% of the portfolio, ranked #103.

Castleview Partners first reported a position in PFE in Q1 2018 and has held it in 20 quarters since. The position peaked at $844K in Q1 2022. 2,934 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Castleview Partners held 16,262 shares of Pfizer worth $457K as of Q1 2026.
  • Castleview Partners bought 2,767 Pfizer shares in Q1 2026, an estimated $73.7K.
  • Pfizer made up 0.23% of Castleview Partners's portfolio in Q1 2026, its #103 holding.
  • Castleview Partners first reported a position in Pfizer in Q1 2018 and has held it in 20 quarters since.
  • Castleview Partners's Pfizer position peaked at $844K in Q1 2022.
  • 2,934 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Castleview Partners's 13F filing for Q1 2026, filed 1 May 2026.